Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07474636 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety Study of HS-10542 for IgA Nephropathy

Study acronym: HS-10542
StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multicenter, randomized, double-blind, parallel, placebo-controlled study and is being conducted to evaluate the efficacy and safety of HS-10542 capsules for primary IgA nephropathy.
Trial Details
NCT Number NCT07474636
Lead Sponsor Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions IgAN, Immunoglobulin A Nephropathy (IgAN), Glomerular Disease
Enrollment 90 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov